Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation

Blood (2021) 138 (Supplement 1): 1788.

https://doi.org/10.1182/blood-2021-146515

Published: 2021

Journal Articles

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Blood (2019) 134 (Supplement_1): 2031.

https://doi.org/10.1182/blood-2019-125646

Published: 2019

Journal Articles

Outcomes and Impact of Donor Lymphocyte Infusion after Reduced Intensity Conditioned-Alemtuzumab Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Mature Lymphoid Malignancies

Charlotte K. Brierley, MD, Francesca M Jones, MD, Katherine Hanlon, MD, Andrew Peniket, MD, Patrick Medd, MD PhD, Andrew Clark, MD, Anne Parker, MD, Sridhar Chaganti, MD PhD, Ram Malladi, MD PhD, Charles Craddock, MD PhD, Robert Danby, MD PhD, Vanderson Rocha, MD PhD

Blood (2016) 128 (22): 3500.

https://doi.org/10.1182/blood.V128.22.3500.3500

Published: 2016

Journal Articles

Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy

Catriona Anne Parker, PhD, Marie Reeves, MSc, Sharon Love, MSc, Jeremy Hancock, PhD, Peter M Hoogerbrugge, MD PhD, Rosemary Sutton, Tom Revesz, MD, Vaskar Saha, PhD FRCP, FRCPath

Blood (2015) 126 (23): 1294.

https://doi.org/10.1182/blood.V126.23.1294.1294

Published: 2015

Journal Articles

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Karl S Peggs, Eleni Tholouli, Ronjon Chakraverty, PhD, Emmanouil Nikolousis, PhD, Adrian Bloor, PhD FRCPath, Stephen Devereux, MD PhD FRCPath, Kim H. Orchard, PhD, Charles Crawley, Anne Parker, Stephen P Robinson, PhD, Frederick Chen, MDPhD, Gordon Cook, MD, Richard E Clark, MBBS MD, Kirsty Thomson, Matthew Cobb, Katy Newton, PhD, Simon Thomas, PhD, Paul Moss, PhD

Blood (2014) 124 (21): 1109.

https://doi.org/10.1182/blood.V124.21.1109.1109

Published: 2014

Journal Articles

ABO Blood Group Mismatch Does Not Affect Survival Or Transfusion Requirements In Patients Undergoing Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation

Charlotte K Brierley, Timothy J Littlewood, Andrew Peniket, Richard Gregg, Janice Ward, Andrew Clark, Anne Parker, Ram Malladi, Patrick G Medd

Blood (2013) 122 (21): 3352.

https://doi.org/10.1182/blood.V122.21.3352.3352

Published: 2013

Journal Articles

Intramuscular PEG-Asparaginase At 1000 U/m 2 Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

Caroline YK Fong, Catriona Anne Parker, Adiba Hussain, Jizhong Liu, Monika Essink, Hans Juergen Kuehnel, Donna L Lancaster, Genevieve Pridham, Debbie Payne, Charlotte O'Horo, Shekhar Krishnan, Jeremy Hancock, Nicholas Goulden, Anthony V. Moorman, Sue Richards, Ajay J Vora, Vaskar Saha, Ashish Narayan Masurekar

Blood (2011) 118 (21): 2573.

https://doi.org/10.1182/blood.V118.21.2573.2573

Published: 2011

Journal Articles

Significantly Lower Cryopreservation Volumes for PBSC Collections Using Spectra Optia® Version 5 Software Compared with the MNC Setting on COBE® Spectra, Particularly When Using Plerixafor for Mobilisation

Mhairi Copland, PhD, BSc, MRCP, FRCPath, Michael Alcorn, Ph.D., Daniela Patton, Ph.D., Allyson Doig, Ph.D., Elizabeth Farrell, Ph.D., Colette Currie, RGN, Joy E Sinclair, RGN, Anne Parker, MD, FRCP, FRCPath, BSc, Kenneth W Douglas, MBChB, BSc, FRCP, FRCPath

Blood (2010) 116 (21): 825.

https://doi.org/10.1182/blood.V116.21.825.825

Published: 2010

Journal Articles

Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study

Ashish Narayan Masurekar, Catriona Anne Parker, BSc, MSc, PhD, Satarupa Choudhuri, Carly Leighton, Jeremy Hancock, Rosemary Sutton, Anthony V. Moorman, PhD, Phil Ancliff, Mary Morgan, MD, Nicholas Goulden, Nina Green, Tamas Revesz, MD, PhD, FRACP, Peter Hoogerbrugge, MD, PhD, Philip Darbyshire, Sharon Love, Vaskar Saha

Blood (2010) 116 (21): 3303.

https://doi.org/10.1182/blood.V116.21.3303.3303

Published: 2010

Journal Articles

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Blood (2010) 116 (16): 3080–3088.

https://doi.org/10.1182/blood-2010-05-286856

Published: 2010

Journal Articles

Results of a Phase I/II-Study on PCR-Based Pre-Emptive Therapy with Valganciclovir or Ganciclovir for Active CMV Infection Following Reduced Intensity Allogeneic Stem Cell Transplantation.

ZiYi Lim, Gordon Cook, Peter R. Johnson, Anne Parker, Mark Zuckerman, Ghulam J. Mufti, David Marks, Antonio Pagliuca

Blood (2007) 110 (11): 5011.

https://doi.org/10.1182/blood.V110.11.5011.5011

Published: 2007

Journal Articles

Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusion after Imatinib Induction To Eradicate Residual Disease in Chronic Myeloid Leukaemia.

Nicholas Heaney, Mhairi Copland, Karen Stewart, Judith Godden, Anne Parker, Grant McQuaker, Graeme Smith, Charles Crawley, Pat Shepherd, Tessa L. Holyoake

Blood (2007) 110 (11): 1097.

https://doi.org/10.1182/blood.V110.11.1097.1097

Published: 2007

Journal Articles

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Adrian Bloor, MD, Gordon Cook, MD, Donald Milligan, MD, Anne Parker, MD, Charles Craddock, MD, Lynny Yung, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1661.

https://doi.org/10.1182/blood.V110.11.1661.1661

Published: 2007

Journal Articles

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Donald Milligan, MD, Ann Hunter, MD, Gordon Cook, MD, Adrian Bloor, MD, Charles Craddock, MD, Lynny Yung, MD, Anne Parker, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1666.

https://doi.org/10.1182/blood.V110.11.1666.1666

Published: 2007

Journal Articles

Compassionate Use of Intrathecal Depot Cytarabine (DepoCyte®) in Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): Report of 11 Cases.

Juan-Manuel Sancho, MD, Anne Parker, MD, Guillermo Deben, MD, Simon Bolam, MD, Eugenio Gimenez, MD, Eva Sanchez-Garcia, MD, Jose-Luis Piñana, MD, Teresa Pascual, MD, Carmen Mateos, MD, Pascual Fernandez-Abellan, MD, Luis Palomera, MD, Josep-Maria Ribera, PhD

Blood (2006) 108 (11): 4545.

https://doi.org/10.1182/blood.V108.11.4545.4545

Published: 2006

Journal Articles

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Ronjon Chakraverty, MD, Maria Dimopoulou, MD, Julie Glanville, MD, Kirsty Thomson, MD, Karl Peggs, MD, Donald Milligan, MD, Gordon Cook, MD, Graham Jackson, MD, Anne Parker, MD, Ann Hunter, MD, Nigel Russell, MD, Rachel Pearce, Stephen Mackinnon, MD

Blood (2006) 108 (11): 2901.

https://doi.org/10.1182/blood.V108.11.2901.2901

Published: 2006

Journal Articles

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Kirsty J. Thomson, MD, Emma C. Morris, MD, Don Milligan, MD, Gordon Cook, MD, Jim Cavet, MD, Charles Craddock, MD, Ann Hunter, MD, Steve Schey, MD, Anne Parker, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Karl S. Peggs, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 401.

https://doi.org/10.1182/blood.V106.11.401.401

Published: 2005

Journal Articles

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Paul Smith, MSc, Raj Chopra, MD, Jim Cavet, MD, Ann Hunter, MD, Anne Parker, MD, Ruth Pettengell, MD, Don Milligan, MD, Emma C. Morris, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 657.

https://doi.org/10.1182/blood.V106.11.657.657

Published: 2005

Journal Articles

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Emma Morris, Kirsty Thomson, Charles Craddock, Prem Mahendra, Donald Milligan, Gordon Cook, Graeme Murray Smith, Anne Parker, Steve Schey, Rajesh Chopra, Christopher Hatton, Jane Tighe, Anne Hunter, Karl Peggs, David Linch, Anthony Goldstone, Stephen Mackinnon

Blood (2004) 104 (13): 3865–3871.

https://doi.org/10.1182/blood-2004-03-1105

Published: 2004

Journal Articles

Psychosocial Screening for Bone Marrow Transplant Recipients.

Matt R. Wild, DClinPsy, Laura Meehan, RGN, Jane Laing, RGN, Anne Parker, MD

Blood (2004) 104 (11): 5025.

https://doi.org/10.1182/blood.V104.11.5025.5025

Published: 2004

NARROW

COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Outcomes and Impact of Donor Lymphocyte Infusion after Reduced Intensity Conditioned-Alemtuzumab Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Mature Lymphoid Malignancies

Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

ABO Blood Group Mismatch Does Not Affect Survival Or Transfusion Requirements In Patients Undergoing Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation

Intramuscular PEG-Asparaginase At 1000 U/m 2 Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

Significantly Lower Cryopreservation Volumes for PBSC Collections Using Spectra Optia® Version 5 Software Compared with the MNC Setting on COBE® Spectra, Particularly When Using Plerixafor for Mobilisation

Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Results of a Phase I/II-Study on PCR-Based Pre-Emptive Therapy with Valganciclovir or Ganciclovir for Active CMV Infection Following Reduced Intensity Allogeneic Stem Cell Transplantation.

Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusion after Imatinib Induction To Eradicate Residual Disease in Chronic Myeloid Leukaemia.

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Compassionate Use of Intrathecal Depot Cytarabine (DepoCyte®) in Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): Report of 11 Cases.

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Psychosocial Screening for Bone Marrow Transplant Recipients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only